Claims for Patent: 7,462,690

Summary for Patent: 7,462,690

Title:	Peptide amidation process
Abstract:	The invention provides a process for amidating a desired peptide comprising cleaving a substrate polypeptide at a X.sub.1-cysteine sequence, wherein X1 is the amino acid at the peptide carboxyl-terminus and cysteine is the first amino acid of a palladium cleavage site comprising the sequence cysteine-X2-X3, wherein X2 is any amino acid, X3 is an amino acid selected from the group consisting of cysteine, histidine, or methionine, and wherein the carboxylterminus of the peptide is amidated upon cleavage at the X1-cysteine sequence.
Inventor(s):	Holmquist; Barton (Eagle, NE), Strydom; Daniel (Lincoln, NE)
Assignee:	Restoragen, Inc. (Lincoln, NE)
Application Number:	10/997,081
Patent Claims:	1. A process to form a carboxyl-terminal amide of a desired peptide comprising contacting a substrate polypeptide and a palladium complex, where the palladium complex is a palladium(II) or palladium(IV) complex, in an acidic medium, wherein the substrate polypeptide comprises the sequence of the desired peptide and the sequence X.sub.1-Cys-X.sub.2-X.sub.3; wherein X.sub.1 is the amino acid at the carboxyl-terminus of the desired peptide, wherein X.sub.1 and X.sub.2 can be any amino acid, and wherein X.sub.3 is selected from the group consisting of cysteine, histidine, and methionine. 2. The process of claim 1, wherein X.sub.2 is alanine. 3. The process of claim 1, wherein the substrate polypeptide comprises two or more X.sub.1-Cys-X.sub.2-X.sub.3 sequences. 4. The process of claim 3, wherein at least one of the X.sub.1-Cys-X.sub.2-X.sub.3 sequences is positioned at the amino-terminus of the desired polypeptide and at least one of the X.sub.1-Cys-X.sub.2-X.sub.3 sequences is positioned at the carboxyl-terminus of the desired peptide. 5. The process of claim 1, wherein the substrate polypeptide has a structure selected from the group consisting of (desired peptide-X.sub.1)-(cysteine-X.sub.2-X.sub.3), (desired peptide-X.sub.1)-(cysteine-X.sub.2-X.sub.3-tail sequence), (leader polypeptide-palladium cleavage site)-(desired peptide-X.sub.1)-(cysteine-X.sub.2-X.sub.3-tail sequence), and (leader polypeptide-palladium cleavage site)-(desired peptide-X.sub.1)-(cysteine-X.sub.2-X.sub.3); wherein X.sub.1 is the amino acid at the carboxyl-terminus of the desired peptide, wherein X.sub.1 and X.sub.2 can be any amino acid, and wherein X.sub.3 is selected from the group consisting of cysteine, histidine, and methionine. 6. The process of claim 5, wherein the tail sequence comprises an amino acid sequence selected from the group consisting of CACLE (SEQ ID NO:12), CACDD (SEQ ID NO:13), CACKK (SEQ ID NO:14), CKCLE (SEQ ID NO:15), CAMLE (SEQ ID NO:16), CAHLE (SEQ ID NO:17), CGHLE (SEQ ID NO:34), and CLHLE (SEQ ID NO:33). 7. The process of claim 5, wherein the (leader polypeptide-palladium cleavage site) comprises cysteine-histidine. 8. The process of claim 7, wherein the leader polypeptide is selected from the group consisting of DDDD (SEQ ID NO:36), DDDK (SEQ ID NO:37), DTRL (SEQ ID NO:38), and GGPR (SEQ ID NO:39). 9. The process of claim 7, wherein a leader sequence is present on the N-terminal side of the cysteine of the cleavage site. 10. The process of claim 9, wherein the leader sequence is DDDDK (SEQ ID NO:7) or GGGGPR (SEQ ID NO:8). 11. The process of claim 1, wherein prior to contacting the substrate polypeptide and the palladium complex, the substrate polypeptide is recombinantly expressed in a host cell as a chimeric protein and is recovered from the host cell in the form of an inclusion body. 12. The process of claim 11, wherein (a) the host cell is E. Coli; and (a) the chimeric protein is selected from the group consisting of T.sub.7-Vg-D.sub.4KCH-GRF (1-44)-CACLE (SEQ ID NO:11), T.sub.7-Vg-D.sub.4KCH-GRF (1-44)-CACDD (SEQ ID NO:18), T.sub.7-Vg-D.sub.4KCH-GRF (1-44)-CACKK (SEQ ID NO:19), T.sub.7-Vg-D.sub.4KCH-GRF (1-44)-CKCLE (SEQ ID NO:41), T.sub.7Vg-D.sub.4KCH-GRF (1- 44)-CAMLE (SEQ ID NO:.sub.20), T.sub.7-Vg-D.sub.4KCH-GRF (1-44)-CAHLE (SEQ ID NO:21), T.sub.7-Vg-D.sub.4KCH-GRF (1-44)-CGHLE (SEQ ID NO:22) and, T.sub.7-Vg-D.sub.4KCH-GRF (1-44)-CLHLE (SEQ ID NO:23). 13. The process of claim 1, wherein the substrate polypeptide is synthetic. 14. The process of claim 1, wherein the substrate polypeptide is naturally occurring. 15. The process of claim 1, wherein the substrate polypeptide is T.sub.7-Vg-D.sub.4KCH-GRF (1-44)-CACLE (SEQ ID NO:11), the acidic medium is malonic acid in a concentration of from about 4M to about 5M, the concentration of substrate polypeptide to malonic acid in the reaction mixture ranges from about 0.1 mg substrate polypeptide/ml malonic acid to about 3 mg substrate polypeptide/ml malonic acid, the palladium complex is Na.sub.2PdCl.sub.4 which is present in the reaction mixture in a molar concentration relative to cysteine in the substrate polypeptide of from about 4 to about 6, the reaction time is from about 60 to about 90 minutes, and the reaction temperature is about 60.degree. C. 16. The process of claim 1, wherein prior to contacting the substrate polypeptide and the palladium complex the substrate polypeptide is expressed recombinantly in a host cell and is recovered from the host cell in the form of an inclusion body. 17. The process of claim 16, wherein the host cell is E. coli. 18. The process of claim 1, wherein the desired peptide is gastrin, calcitonin, luteinizinghormone-releasing hormone, pancreatic polypeptide, endothelin, corticotropin releasing factor, neuropeptide Y, atrial naturetic peptide, amylin, galanin, a somatostatin, vasoactive intestinal peptide or insulin. 19. The process of claim 18, wherein prior to contacting the substrate polypeptide and the palladium complex the substrate polypeptide is expressed recombinantly in a host cell and is recovered from the host cell in the form of an inclusion body. 20. The process of claim 1, wherein the desired peptide is GLP-2, GLP-1, GRF, PTH, parathyroid hormone related hormone, ACTH, an enkephalin, an endorphin, an exendin, an amylin, an opioid, gaegurin 5 or 6, brevinin 1, any one of ranatuerin 1 through 9, an esculetin, GIP, glucagon, motilin, a thymopoietin, a thymosin, ubiquitin, serum thymic factor, thymic humoral factor, neurotensin, or tuftsin. 21. The process of claim 20, wherein prior to contacting the substrate polypeptide and the palladium complex the substrate polypeptide is expressed recombinantly in a host cell and is recovered from the host cell in the form of an inclusion body. 22. The process of claim 21, wherein the host cell is E. coli. 23. The process of claim 1, wherein the acidic medium is an acidic organic solvent. 24. The process of claim 1 or 23, wherein the palladium complex is a Palladium(II) complex selected from the group consisting of Na.sub.2PdCl.sub.4; cis-[Pd(en)Cl.sub.2]; cis-[Pd(bp)Cl.sub.2]; cis-[Pd(phen)Cl.sub.2]; cis-[Pd(pn)Cl.sub.2]; cis-[Pd(pic)Cl.sub.2]; cis-[Pd(dtco-OH)Cl.sub.2cis-[Pd(en)(OH.sub.2).sub.2].sub.2+, cis-[Pd(pn)(HO.sub.2).sub.2].sub.2+, cis-[Pd(pic)(HO.sub.2).sub.2].sub.2+, cis-[Pd(bp)(OH.sub.2).sub.2].sub.2+, cis-[Pd(phen)(HO.sub.2).sub.2].sub.2+, cis-[Pd(dtco-OH)(OH.sub.2).sub.2].sub.2+; and[Pd(OH.sub.2).sub.3(OH)](NO.sub.3). 25. The process of claim 23 wherein the acidic organic solvent is an monocarboxylic acid, dicarboxylic acid, tricarboxylic acid, hydroxysubstituted acid, uronic acid, aldonic acid or aldaric acid. 26. The process of claim 23, wherein the organic solvent is combined with an inorganic acid selected from the group consisting of HCl, H.sub.3PO.sub.4, H.sub.2SO.sub.4, and HClO.sub.4. 27. The process of claim 23, wherein the molar ratio of palladium complex to Cys is from about 0.1 to about 20. 28. The process of claim 27, wherein the substrate polypeptide and palladium complex are contacted from about one to about two hours. 29. The process of claim 27, wherein the substrate polypeptide and palladium complex are contacted from about three to about six hours. 30. The process of claim 28, wherein the temperature is maintained at about 50.degree. C. to about 70.degree.C. 31. A process of producing a carboxyl-terminal amidated desired peptide comprising cleaving a substrate polypeptide concurrently at (i) a first cleavage site which links the N-terminus of a first amino acid sequence defining the desired peptide to the carboxyl terminus of a second amino acid sequence defining a leader sequence and (ii) at a second X.sub.1-cysteine cleavage site, wherein X.sub.1 is the amino acid at the peptide carboxy-terminus and the cysteine is the first amino acid of a tail sequence comprising the sequence cysteine -X.sub.2-X.sub.3, where X.sub.2 is any amino acid and X.sub.3 is an amino acid selected from the group consisting of cysteine, histidine, and methionine, by reacting the substrate polypeptide in a reaction mixture of an acidic organic solvent and a palladium complex, where the palladium complex is a palladium(II) or palladium(IV) complex, wherein the concentration of the organic solvent is between about 2 to about 22 molar and the carboxy-terminus of the desired peptide is amidated upon cleavage at the second X.sub.1-cysteine cleavage site.

Details for Patent 7,462,690

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2022-05-24